Abstract 123P
Background
To study the relationship between prognostic nutritional index (PNI) and clinicopathological factors in gastroesophageal junction cancer patients with postoperative anastomotic leakage and the clinical significance of PNI in predicting the survival of patients with postoperative anastomotic leakage.
Methods
Clinicopathological and follow-up data of 115 gastroesophageal junction cancer patients with anastomotic leakage after radical surgery in the Department of Thoracic Surgery, the 4th Hospital of Hebei Medical University from January 1 2004 to December 31 2013 were retrospectively analyzed. PNI values were calculated [PNI = absolute lymphocyte count (109/L) x 5 + serum albumin (g/L)], and was grouped according to the PNI mean value. Relationships of PNI with patient gender, age, tumor stage, tumor differentiation, tumor location, lymph node metastasis were analyzed. For survival analysis, log-rank method was used for univariate analysis, and Cox method was used for multivariate analysis.
Results
The mean PNI of patients with anastomotic leakage was 48.51 (43.25∼56.25). The 5-year survival rate of patients with PNI ≤48.51 was 58.9%, and the 5-year survival rate for patients with PNI>48.51 was 59.3%. There was no significant difference between the two groups (χ2=0.127, P=0.722). Univariate and multivariate analysis showed that N stage is an independent risk factor for the prognosis of patients with PNI≤48.51. Postoperative adjuvant treatment is an independent risk factor for the survival of patients with PNI>48.51. P for interaction between PNI and treatment modality: P=0.037.
Conclusions
The independent prognostic factors of patients with esophagogastric junction adenocarcinoma combined with anastomotic leakage are N stage and adjuvant treatment for PNI≤48.51 and PNI>48.51 group, respectively. For patients with esophagogastric junction adenocarcinoma combined with anastomotic leakage, PNI is an important factor for guiding the selection of appropriate postoperative treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Fourth Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session